PFIZER INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PFIZER INC (PFE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $26.75 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- PFIZER INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $26.75, a 20.20% decline from fiscal 2024.
- PFIZER INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $33.52, a 14.86% decline from fiscal 2023.
- PFIZER INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $39.37, a 14.05% increase from fiscal 2022.
- PFIZER INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $34.52, a 0.38% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $26.75 10-K · filed 2026-02-26 |
| 2024-12-31 | $33.52 10-K · filed 2025-02-27 |
| 2023-12-31 | $39.37 10-K · filed 2024-02-22 |
| 2022-12-31 | $34.52 10-K · filed 2023-02-23 |
| 2021-12-31 | $34.39 10-K · filed 2022-02-24 |
| 2020-12-31 | $35.49 10-K · filed 2021-02-25 |
| 2019-12-31 | $37.67 10-K · filed 2020-02-27 |
| 2018-12-31 | $33.96 10-K · filed 2019-02-28 |
| 2017-12-31 | $34.26 10-K · filed 2018-02-22 |
| 2016-12-31 | $33.18 10-K · filed 2017-02-23 |
| 2015-12-31 | $31.24 10-K · filed 2016-02-29 |
| 2014-12-31 | $26.36 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |